A longer-duration Phase 2 clinical trial of ABI-5366
Latest Information Update: 17 Oct 2025
At a glance
- Drugs ABI 5366 (Primary)
- Indications Herpes simplex virus type 2 infections
- Focus Therapeutic Use
Most Recent Events
- 17 Oct 2025 New trial record
- 08 Aug 2025 According to Assembly Biosciences media release, the company expect to initiate the phase 2 studies in mid-2026.